Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients - Vigipallia

0 avis

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Archive ouverte

Nicolini, Franck Emmanuel | Dulucq, Stéphanie | Boureau, Lisa | Cony-Makhoul, Pascale | Charbonnier, Aude | Escoffre-Barbe, Martine | Rigal-Huguet, Françoise | Coiteux, Valérie | Varet, Bruno | Dubruille, Viviane | Lenain, Pascal | Rousselot, Philippe | Rea, Delphine | Guerci-Bresler, Agnès | Legros, Laurence | Liu, Jixing | Gardembas, Martine | Ianotto, Jean-Christophe | Turlure, Pascal | Johnson-Ansah, Hyacinthe | Martiniuc, Juliana | Jardel, Henry | Joly, Bertrand | Zunic, Patricia | Henni, Tawfiq | Villemagne, Bruno | Berger, Marc G. | Cayssials, Emilie | Guilhot, François | Larosa, Fabrice | Guilhot, Joëlle | Etienne, Gabriel | Mahon, François-Xavier

Edité par CCSD ; American Association for Cancer Research -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Archive ouverte | Guilhot, Francois | CCSD

International audience

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Archive ouverte | Rea, Delphine | CCSD

International audience

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Archive ouverte | Rea, Delphine | CCSD

International audience

Chargement des enrichissements...